You need to Turn on Javascript or upgrade your Flash Player!
To Fully experience the Rich Media Solutions of this website, you must make sure that JavaScript is enabled.
You may also need to upgrade your Flash Player.
You can upgrade your flash player by Clicking Here »
How much IG to prescribe differs for each individual based on a variety of clinical and non-clinical factors, as well as physician discretion.
Immune globulin (IG) is used to treat a wide range of disorders. While the most common use of IG therapy is in treating primary immune deficiencies, its efficacy in numerous other disorders is well-documented.
Knowing what side effects, from mild to serious, to expect during and after immune globulin infusions can prepare patients and their caregivers for treatment changes to mitigate their impact.
With the FDA approval of SCIG therapy in 2006, many patients now have the choice between SCIG and IVIG infusions. Understanding the differences between the two treatment modalities will help healthcare providers recommend the right one for their patients.
During the past three decades, IVIG has proven an effective treatment for a wide range of autoimmune diseases, and it is now believed that IVIG may have clinical uses for a broader range of medical conditions.